Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

SIRT5-mediated FDX1 desuccinylation confers cuproptosis resistance in lung adenocarcinoma.

Qifan Hu | Zuorui Wang | Wenxin Deng | Lei Wang | Jiayuan Chen | Hui Wang | Lei Jiang | Zhuo Lu | Yikai Zhao | Jia Hou | Mingxi Gan | Jing Xu | Yaoguang Hua | Yi Yuan | Menglin Huang | Lanxi Bai | Jian-Bin Wang | Bentong Yu
Cell reports | 2026

Cuproptosis, a copper-dependent cell death process induced by excessive copper, represents an emerging therapeutic strategy in oncology. However, tumor-specific molecular pathways regulating this process remain poorly defined. Here, we demonstrate that copper levels are elevated in lung adenocarcinoma (LUAD), and LUAD cell lines exhibit increased resistance to cuproptosis. Mechanistically, elevated copper stress promotes the expression of the desuccinylase SIRT5 while reducing global succinylation in LUAD cells. Furthermore, we found that SIRT5 is a critical mediator of cuproptosis through the desuccinylation modification on ferredoxin1 (FDX1) protein at Lys84. This modification triggers TRIM8-mediated ubiquitination, leading to FDX1 proteasomal degradation and enhanced cuproptosis resistance. These results reveal the important role of SIRT5 in LUAD cuproptosis resistance. Notably, combining the SIRT5 inhibitor MC3482 with the cuproptosis inducer Elesclomol-Cu synergistically suppresses tumor growth in vivo, suggesting a promising therapeutic strategy. These findings elucidate mechanisms underlying cuproptosis resistance and propose a novel treatment approach for LUAD.

Pubmed ID: 42228571

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Lipoic Acid antibody (antibody)

RRID:AB_880635

This polyclonal targets Lipoic Acid antibody

View all literature mentions

Pan anti-succinyllysine antibody (antibody)

RRID:AB_2687628

This polyclonal targets succinyllysine

View all literature mentions

SIRT5 antibody (antibody)

RRID:AB_2882530

This monoclonal targets SIRT5

View all literature mentions

K48-linkage Specific Polyubiquitin (D9D5) Rabbit mAb (antibody)

RRID:AB_10859893

This monoclonal targets K48-linkage Specific Polyubiquitin (D9D5) Rabbit mAb

View all literature mentions

VDAC1/Porin antibody (antibody)

RRID:AB_3672910

This monoclonal targets VDAC1/Porin

View all literature mentions

FLAG (antibody)

RRID:AB_1960908

This monoclonal targets FLAG

View all literature mentions

TRIM8 antibody (antibody)

RRID:AB_2880877

This polyclonal targets TRIM8

View all literature mentions

DLAT antibody (antibody)

RRID:AB_3672565

This polyclonal targets DLAT

View all literature mentions

FDX1 antibody (antibody)

RRID:AB_3670701

This recombinant targets FDX1

View all literature mentions

Anti-Acetyllysine Mouse mAb (antibody)

RRID:AB_2940830

This monoclonal targets Acetyllysine

View all literature mentions